{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Goodman AC"],"funding":["Moore Family Foundation","Rocky Vista University","Patten-Davis Foundation","NIH NCI"],"pagination":["14"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC12844009"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["16(1)"],"pubmed_abstract":["<h4>Background/objectives</h4>Immunotherapy has significantly improved clinical outcomes for patients with late-stage melanoma, yet a substantial portion of patients fail to respond to these treatments. The variability in responses to immunotherapy, both among individual patients and across different melanoma subtypes, underscores the need to explore the influence of circulating factors such as oxylipins on therapeutic outcomes. This study investigated the relationship between serum oxylipin profiles and response to immune checkpoint inhibitor therapy in melanoma subtypes to identify potential metabolic biomarkers for treatment response.<h4>Methods</h4>In a retrospective cohort study, serum samples from 43 stage III and stage IV melanoma patients treated at the University of Colorado Hospi"],"journal":["Metabolites"],"pubmed_title":["Profiling Serum Oxylipin Metabolites Across Melanoma Subtypes and Immunotherapy Responders."],"pmcid":["PMC12844009"],"funding_grant_id":["P30CA046934","Tracks & Special Programs Department","CU Skin Cancer Biorepository","CU Center for Rare Melanomas"],"pubmed_authors":["Goodman AC","Turner JA","Robinson WA","Michel KM","MacBeth ML","Tobin RP","Couts KL"],"additional_accession":[]},"is_claimable":false,"name":"Profiling Serum Oxylipin Metabolites Across Melanoma Subtypes and Immunotherapy Responders.","description":"<h4>Background/objectives</h4>Immunotherapy has significantly improved clinical outcomes for patients with late-stage melanoma, yet a substantial portion of patients fail to respond to these treatments. The variability in responses to immunotherapy, both among individual patients and across different melanoma subtypes, underscores the need to explore the influence of circulating factors such as oxylipins on therapeutic outcomes. This study investigated the relationship between serum oxylipin profiles and response to immune checkpoint inhibitor therapy in melanoma subtypes to identify potential metabolic biomarkers for treatment response.<h4>Methods</h4>In a retrospective cohort study, serum samples from 43 stage III and stage IV melanoma patients treated at the University of Colorado Hospi","dates":{"release":"2025-01-01T00:00:00Z","publication":"2025 Dec","modification":"2026-06-15T03:18:34.37Z","creation":"2026-06-15T03:08:48.158Z"},"accession":"S-EPMC12844009","cross_references":{"pubmed":["41590622"],"doi":["10.3390/metabo16010014"]}}